$CSLM
CSLM ACQUISITION CORP.

2023 Q2 Form 10-Q Financial Statement

#000119312523212348 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $119.1K
YoY Change 0.0%
Gross Profit -$119.1K
YoY Change 0.0%
Gross Profit Margin
Selling, General & Admin $220.0K $209.2K
YoY Change -43.22%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $225.6K $216.0K
YoY Change -44.72% 11835.91%
Operating Profit -$225.6K
YoY Change -44.72%
Interest Expense $2.320M $1.754M
YoY Change 691.24%
% of Operating Profit
Other Income/Expense, Net $2.319M $10.00
YoY Change
Pretax Income $2.090M $1.538M
YoY Change -1918.18% -85074.59%
Income Tax
% Of Pretax Income
Net Earnings $2.093M $1.538M
YoY Change -1921.06% -85074.59%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.09 $0.06
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $199.4M $195.0M
YoY Change 58610.95% 974961700.0%
Cash & Equivalents $173.9K $224.5K
Short-Term Investments $199.2M $194.8M
Other Short-Term Assets $300.0K $494.8K
YoY Change -38.3%
Inventory
Prepaid Expenses $300.0K $494.8K
Receivables
Other Receivables $28.46K $28.46K
Total Short-Term Assets $199.7M $195.5M
YoY Change 23371.56% 977578225.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets -$5.550K $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $199.7M $195.5M
Total Long-Term Assets -$5.550K $0.00
Total Assets $199.7M $195.5M
YoY Change 3.41% 23105.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $83.16K $8.185K
YoY Change
Accrued Expenses $373.2K $308.0K
YoY Change 40.74% 526.28%
Deferred Revenue
YoY Change
Short-Term Debt $600.0K $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.700M $7.237M
YoY Change 1313.22% 735.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.700M $7.237M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $7.704M $7.237M
YoY Change 7.21% 735.02%
SHAREHOLDERS EQUITY
Retained Earnings -$7.202M -$6.490M
YoY Change 18.47% 13102.94%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.202M -$6.489M
YoY Change
Total Liabilities & Shareholders Equity $199.7M $195.5M
YoY Change 3.41% 23105.51%

Cashflow Statement

Concept 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income $2.093M $1.538M
YoY Change -1921.06% -85074.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $680.0K $355.1K
YoY Change -1214.02% 1775400.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$1.060M $0.00
YoY Change
Cash From Investing Activities -$1.060M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 300.0K -410.9K
YoY Change
NET CHANGE
Cash From Operating Activities 680.0K 355.1K
Cash From Investing Activities -1.060M 0.000
Cash From Financing Activities 300.0K -410.9K
Net Change In Cash -80.00K -55.85K
YoY Change 31.06% -279350.0%
FREE CASH FLOW
Cash From Operating Activities $680.0K $355.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001875493
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41219
dei Entity Registrant Name
EntityRegistrantName
CSLM ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1602789
dei Entity Address Address Line1
EntityAddressAddressLine1
2400 E. Commercial Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Ft. Lauderdale
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33308
dei City Area Code
CityAreaCode
954
dei Local Phone Number
LocalPhoneNumber
315-9381
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Consilium Acquisition Corp I Ltd.
dei Security12b Title
Security12bTitle
Class A ordinary shares, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CSLM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173914
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
224474
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
300020
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
494844
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
28462
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
28462
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
199192054
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
194767885
CY2023Q2 us-gaap Assets
Assets
199694450
CY2022Q4 us-gaap Assets
Assets
195515665
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
83158
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8185
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
373223
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
307966
CY2023Q2 cslm Accrued Offering Costs Current
AccruedOfferingCostsCurrent
0
CY2022Q4 cslm Accrued Offering Costs Current
AccruedOfferingCostsCurrent
279678
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
600000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
6309
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
6641250
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
6641250
CY2023Q2 us-gaap Liabilities
Liabilities
7703940
CY2022Q4 us-gaap Liabilities
Liabilities
7237079
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
199192054
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
194767885
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7202018
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6489773
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-7201544
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-6489299
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
199694450
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
195515665
CY2023Q2 us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
119110
CY2022Q2 us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
119110
us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
236912
us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
221205
CY2023Q2 cslm Dues And Subscriptions
DuesAndSubscriptions
37794
CY2022Q2 cslm Dues And Subscriptions
DuesAndSubscriptions
13333
cslm Dues And Subscriptions
DuesAndSubscriptions
140940
cslm Dues And Subscriptions
DuesAndSubscriptions
121488
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
62906
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
255027
us-gaap Professional Fees
ProfessionalFees
326532
us-gaap Professional Fees
ProfessionalFees
289191
CY2023Q2 cslm Bank Fees General And Administrative Expenses
BankFeesGeneralAndAdministrativeExpenses
5813
CY2022Q2 cslm Bank Fees General And Administrative Expenses
BankFeesGeneralAndAdministrativeExpenses
20685
cslm Bank Fees General And Administrative Expenses
BankFeesGeneralAndAdministrativeExpenses
7861
cslm Bank Fees General And Administrative Expenses
BankFeesGeneralAndAdministrativeExpenses
20690
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
225623
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
408155
us-gaap Operating Expenses
OperatingExpenses
712245
us-gaap Operating Expenses
OperatingExpenses
652574
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-225623
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-408155
us-gaap Operating Income Loss
OperatingIncomeLoss
-712245
us-gaap Operating Income Loss
OperatingIncomeLoss
-652574
CY2023Q2 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
433018
CY2022Q2 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
293206
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
2538270
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
352851
CY2023Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
1885899
CY2022Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
0
us-gaap Investment Income Dividend
InvestmentIncomeDividend
1885899
us-gaap Investment Income Dividend
InvestmentIncomeDividend
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2318917
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
293206
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4424169
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
352851
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
2093294
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-114949
us-gaap Net Income Loss
NetIncomeLoss
3711924
us-gaap Net Income Loss
NetIncomeLoss
-299723
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-6489299
CY2023Q1 cslm Remeasurement Of Class A Ordinary Shares Subject To Redemption To Redemption Value
RemeasurementOfClassAOrdinarySharesSubjectToRedemptionToRedemptionValue
-2105252
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1618630
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6975921
CY2023Q2 cslm Remeasurement Of Class A Ordinary Shares Subject To Redemption To Redemption Value
RemeasurementOfClassAOrdinarySharesSubjectToRedemptionToRedemptionValue
-2318917
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
2093294
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-7201544
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-24154
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17472540
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7942500
CY2022Q1 cslm Remeasurement Of Class A Ordinary Shares Subject To Redemption To Redemption Value
RemeasurementOfClassAOrdinarySharesSubjectToRedemptionToRedemptionValue
-30876700
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-184774
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5670588
CY2022Q2 cslm Remeasurement Of Class A Ordinary Shares Subject To Redemption To Redemption Value
RemeasurementOfClassAOrdinarySharesSubjectToRedemptionToRedemptionValue
-293206
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-114949
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6078743
us-gaap Net Income Loss
NetIncomeLoss
3711924
us-gaap Net Income Loss
NetIncomeLoss
-299723
cslm Insurance Expense Amortization
InsuranceExpenseAmortization
221205
cslm Dues And Subscriptions Expense Amortization
DuesAndSubscriptionsExpenseAmortization
43059
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
2538270
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
352851
cslm Accrued Dividends On Marketable Securities Held In Trust Account
AccruedDividendsOnMarketableSecuritiesHeldInTrustAccount
824763
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-194824
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1007000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
74973
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
65257
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
216002
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
6309
cslm Increase Decrease In Accrued Offering Costs
IncreaseDecreaseInAccruedOfferingCosts
-279678
cslm Increase Decrease In Accrued Offering Costs
IncreaseDecreaseInAccruedOfferingCosts
-410948
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
410576
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1590256
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
393448136
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
383367500
cslm Payment For Purchase Of Treasury Securities
PaymentForPurchaseOfTreasurySecurities
-392387000
cslm Payment For Purchase Of Treasury Securities
PaymentForPurchaseOfTreasurySecurities
-191720000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1061136
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-191647500
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189750000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7942500
cslm Payment Of Underwriting Fee
PaymentOfUnderwritingFee
3795000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
600000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-206313
cslm Due From Related Party Classified As Financing Activities
DueFromRelatedPartyClassifiedAsFinancingActivities
25000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
138826
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
600000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
193577361
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50560
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
339606
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
224474
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173914
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
339626
cslm Remeasurement Of Ordinary Shares Subject To Possible Redemption
RemeasurementOfOrdinarySharesSubjectToPossibleRedemption
4424169
cslm Remeasurement Of Ordinary Shares Subject To Possible Redemption
RemeasurementOfOrdinarySharesSubjectToPossibleRedemption
31169906
cslm Initial Fair Value Of Ordinary Shares Subject To Possible Redemption
InitialFairValueOfOrdinarySharesSubjectToPossibleRedemption
160830445
cslm Deferred Underwriter Fee Payable
DeferredUnderwriterFeePayable
0
cslm Deferred Underwriter Fee Payable
DeferredUnderwriterFeePayable
6641250
cslm Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
-279678
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
one right to acquire one-tenth of an Ordinary Share, and one-half of one redeemable warrant
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2022Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
189750000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7942500
CY2022Q2 cslm Class Of Warrants Or Rights Redemption Price Per Unit
ClassOfWarrantsOrRightsRedemptionPricePerUnit
10
cslm Companys Operating Account
CompanysOperatingAccount
2250000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
191647500
CY2023Q2 cslm Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated
PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated
1
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173914
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
224474
CY2023Q2 cslm Net Working Capital Deficit
NetWorkingCapitalDeficit
-560294
CY2022Q4 cslm Net Working Capital Deficit
NetWorkingCapitalDeficit
151951
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
20
CY2022Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
191647500
CY2022Q1 cslm Term Of Restricted Investments
TermOfRestrictedInvestments
P185D
CY2022Q1 cslm Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated
PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated
1
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
2093294
CY2023Q2 cslm Remeasurement Of Class A Ordinary Shares Subject To Redemption To Redemption Value
RemeasurementOfClassAOrdinarySharesSubjectToRedemptionToRedemptionValue
-2318917
CY2023Q2 cslm Net Income Loss Including Remeasurement Of Temporary Equity To Redemption Value
NetIncomeLossIncludingRemeasurementOfTemporaryEquityToRedemptionValue
-225623
us-gaap Net Income Loss
NetIncomeLoss
3711924
cslm Remeasurement Of Class A Ordinary Shares Subject To Redemption To Redemption Value
RemeasurementOfClassAOrdinarySharesSubjectToRedemptionToRedemptionValue
-4424169
cslm Net Income Loss Including Remeasurement Of Temporary Equity To Redemption Value
NetIncomeLossIncludingRemeasurementOfTemporaryEquityToRedemptionValue
-712245
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-114949
CY2022Q2 cslm Remeasurement Of Class A Ordinary Shares Subject To Redemption To Redemption Value
RemeasurementOfClassAOrdinarySharesSubjectToRedemptionToRedemptionValue
-293206
CY2022Q2 cslm Net Income Loss Including Remeasurement Of Temporary Equity To Redemption Value
NetIncomeLossIncludingRemeasurementOfTemporaryEquityToRedemptionValue
-408155
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
18975000
CY2022 cslm Fair Value Allocated To Public Warrants
FairValueAllocatedToPublicWarrants
-4524000
CY2022 cslm Fair Value Allocated To Rights
FairValueAllocatedToRights
-12948540
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.50
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed Federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. At June 30, 2023 and December 31, 2022, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div>
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
191647500
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7942500
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2022Q4 us-gaap Notes Payable
NotesPayable
0
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
199192054
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
194767885

Files In Submission

Name View Source Status
cslm-20230630_lab.xml Edgar Link unprocessable
0001193125-23-212348-index-headers.html Edgar Link pending
0001193125-23-212348-index.html Edgar Link pending
0001193125-23-212348.txt Edgar Link pending
0001193125-23-212348-xbrl.zip Edgar Link pending
cslm-20230630.xsd Edgar Link pending
d538631d10q.htm Edgar Link pending
d538631dex311.htm Edgar Link pending
d538631dex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
cslm-20230630_def.xml Edgar Link unprocessable
cslm-20230630_cal.xml Edgar Link unprocessable
cslm-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d538631d10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending